BRCA or HRR+ Mutated Ovarian Cancer Patients
1 clinical trials · Condition
◉ Watch BRCA or HRR+ Mutated Ovarian Cancer Patients
| Record | Firm | Date |
|---|---|---|
| To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (NCT02476968) | AstraZeneca | 2015-09-28 |
Track BRCA or HRR+ Mutated Ovarian Cancer Patients automatically
Every clearance here is in the API, with alerts when new ones post.